Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer

doi:10.4251/wjgo.v16.i6.2449

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2098)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-6) series.

Item

Count

PDF

HTML

1318

Figures (1-4)

177

Tables (1-6)

143

Sum=1713

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

225

Sum=292

Jun 15, 2024 (publication date) through Jan 23, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Jun 15, 2024; 16(6): 2449-2462
Published online Jun 15, 2024. doi: 10.4251/wjgo.v16.i6.2449

Full Size Figure Download Figure

Figure 2 Kaplan-Meier analysis. A: Kaplan-Meier curves of progression-free survival in patients treated with Regorafenib (R), regorafenib plus programmed death-1 inhibitors (RP), fruquintinib (F), and fruquintinib plus programmed death-1 (FP); B: Kaplan-Meier curves of overall survival in patients treated with R, RP, F, and FP. ^aP < 0.05, and the difference is statistically significant. F: Fruquintinib; R: Regorafenib; FP: Fruquintinib plus programmed death-1 inhibitors; RP: Regorafenib plus programmed death-1 inhibitors.

Citation: An TQ, Qiu H, Zhou QB, Zong H, Hu S, Lian YG, Zhao RH. Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer. World J Gastrointest Oncol 2024; 16(6): 2449-2462
URL: https://www.wjgnet.com/1948-5204/full/v16/i6/2449.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i6.2449